Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00220909 · ClinicalTrials.gov registry record · Phase 4
Lansoprazole Preventing Gastroduodenal Stress Ulcerations
A Phase 4 study, sponsored by Temple University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT00220909: Clinical Trial Phase 4 study, sponsored by Temple University.
NCT00220909 is a Phase 4 study that was terminated before completion, run by Temple University. The registered enrollment target is 40 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00220909, a Phase 4 study, was terminated before completion, sponsored by Temple University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine whether lansoprazole, administered intravenously, can protect patients undergoing cardiac surgery from the development of and/or progression of previously undetected acid/peptic disorders (erosive esophagitis, gastric ulcer, duodenal ulcer, diffuse gastritis, duodenitis) as measured by the Lanza score and LA classification for esophageal injury. The secondary objectives of this study are: 1. To determine if intravenous lansoprazole protects against the development of clinically important gastrointestinal bleeding in this population (overt bleeding or requiring blood transfusion). 2. To determine if intravenous lansoprazole maintains the intragastric pH above that for placebo throughout the study period.
Interventions
- DRUG Lansoprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2005-09 |
| Est. Completion | 2006-01 |
| Phase | Phase 4 |
Why NCT00220909 stopped before completion
NCT00220909 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which Lansoprazole is the first listed.
NCT00220909 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00220909 about?
NCT00220909 is a clinical study titled "Lansoprazole Preventing Gastroduodenal Stress Ulcerations". The primary objective of this study is to determine whether lansoprazole, administered intravenously, can protect patients undergoing cardiac surgery from the development of and/or progression of previously undetected acid/peptic disorders (erosive esophagitis, gastric ulcer, duodenal ulcer, diffuse...
What is the current status of trial NCT00220909?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2005-09. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00220909?
The interventions under investigation include: Lansoprazole (DRUG).
Who is sponsoring clinical trial NCT00220909?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00220909's enrollment target sits among peer trials
40 1397th of 2000 higher than 533 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia